Delcath Systems Reports Second Quarter 2024 Results and Business Highlights
Delcath Systems to Host Second Quarter 2024 Earnings Call
Now, a team of researchers led by the Norwegian University of Science and Technology has preliminary evidence that targeting a protein kinase called TAK1 (transforming growth factor beta-activated kinase 1) could offer a new treatment strategy for multiple myeloma. They described their research in the journal Oncotarget.
EMA’s human medicines committee (CHMP) recommended seven medicines for approval at its September 2020 meeting.
CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing therapeutics and pharmaceutical products in China, U.S., and throughout the world, announces the product launch of EVOMELA® (melphalan for injection) in China which is the first commercial product for the Company.
Takeda has stumbled again in its quest to build up the blockbuster potential of its multiple myeloma drug Ninlaro. The pharma giant says the drug combined with dexamethasone failed to provide significant help for patients with rare cases of systemic light-chain amyloidosis, so now they’re scrapping the entire Phase III program.
Alnylam Pharmaceuticals has entered an agreement with Medison Pharma to commercialise its RNAi therapeutic Onpattro in Israel. Novartis has signed an agreement to use Kinaxis’ RapidResponse platform, a Cloud-based software that provides country-specific product expiry monitoring and planning across a company’s global network.
Spectrum Pharmaceuticals sells marketed drugs to Aurobindo subsidiary for up to $300M
Darzalex also significantly improved overall response rates compared to VMP alone (91 percent versus 74 percent), including more than doubling rates of stringent complete response (18 percent vs 7 percent) and boosting complete response or better (43 percent vs 24 percent).